Shanghai Biomaterials Research & Testing Center, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200023, China.
Toxicol Lett. 2011 Aug 10;205(1):55-61. doi: 10.1016/j.toxlet.2011.04.034. Epub 2011 May 10.
As the biosafety of nanotechnology becomes a growing concern, the in vivo nanotoxicity of nanoparticles (NPs) has been drawn an increasing attention. Titanium dioxide nanoparticles (TiO(2)-NPs) have been developed for versatile use, but the pharmacokinetics of intravenously administered TiO(2)-NPs have not been investigated extensively. In the present study, the rutile-type TiO(2)-NPs with a size about 20nm were labeled with CF680 and (125)I. The labeled TiO(2)-NPs were injected in mice or rats with the concentration of 1mg/ml and the dose of 10mg/kg body weight and their tissue distribution and excretion were investigated by using ex vivo fluorescent imaging, γ-counter and TEM. The results indicated that the TiO(2)-NPs mainly accumulated in liver and spleen and could be retained for over 30days in these tissues due to the phagocytosis by macrophages. The excretion assay found that the excretory rate of TiO(2)-NPs through urine was higher than that of feces, indicating that renal excretion was the main excretion pathway of TiO(2)-NPs. Overall results of the present study provided important information on distribution and excretion of TiO(2)-NPs in vivo, which would greatly promote the pharmacokinetics and in vivo nanotoxicity research of TiO(2)-NPs.
随着纳米技术的生物安全性日益受到关注，纳米颗粒（NPs）的体内纳米毒性引起了越来越多的关注。二氧化钛纳米颗粒（TiO2-NPs）已经得到了广泛的开发和应用，但其静脉内给予后的药代动力学尚未得到广泛研究。在本研究中，我们使用 CF680 和（125）I 对约 20nm 大小的锐钛矿型 TiO2-NPs 进行了标记。将标记的 TiO2-NPs 以 1mg/ml 的浓度和 10mg/kg 体重的剂量注入小鼠或大鼠体内，通过离体荧光成像、γ计数器和 TEM 研究其组织分布和排泄情况。结果表明，TiO2-NPs 主要在肝脏和脾脏中积累，并由于巨噬细胞的吞噬作用而在这些组织中保留超过 30 天。排泄试验发现，TiO2-NPs 通过尿液的排泄率高于粪便，表明肾脏排泄是 TiO2-NPs 的主要排泄途径。本研究的总体结果提供了 TiO2-NPs 在体内的分布和排泄的重要信息，这将极大地促进 TiO2-NPs 的药代动力学和体内纳米毒性研究。
